2-deoxyglucose AUC | *None* | | 0 to Infinity | *None*
| |

absolute neutrophil count | ANC | | 0 to Infinity | *None*
| |

acceleration rate of early transmitral filling wave | MV acc | (m/s2) | -Infinity to Infinity | Echocardiography: Mouse | |

acetoacetate oxidation | ACT OX | (µMol/min/g) | -Infinity to Infinity | *None*
| |

adenosine diphosphate | adp | | -Infinity to Infinity | *None*
| |

adenosine monophosphate | AMP | | -Infinity to Infinity | *None*
| |

adenosine triphosphate | ATP | | -Infinity to Infinity | *None*
| |

adiponectin | *None* | (mg/dL) | -Infinity to Infinity | *None*
| |

Age | *None* | (w) | 0 to 1092 | *None*
| |

alanine | *None* | | 0 to Infinity | *None*
| |

alanine amino transferase | ALT | (U/L) | 0 to Infinity | *None*
| |

alanine aminotransferase | ALT | (U/L) | 0 to Infinity | *None*
| |

Alanine transaminase, blood | *None* | | 0 to Infinity | *None*
| |

albumin | *None* | (g/dL) | -Infinity to Infinity | *None*
| |

albumin to creatinine ratio | ACR | (mg/g) | 0 to 10000 | *None*
| |

albumin, blood | *None* | | 0 to Infinity | *None*
| |

alkaline phosphatase | ALP | (U/L) | 0 to Infinity | *None*
| |

alkaline phosphatase, blood | *None* | | 0 to Infinity | *None*
| |

alpha ketoglutarate glutamate exchange rate | Vx | (µMol/min/g) | -Infinity to Infinity | *None*
| |

amino acids, branched-chain | *None* | | 0 to Infinity | *None*
| |

amino acids, essential | *None* | | 0 to Infinity | *None*
| |

amino acids, gluconeogenic | *None* | (U/L) | -Infinity to Infinity | *None*
| |

amino acids, glyconeogenic | glyconeogenic AA | | 0 to Infinity | *None*
| |

amino acids, nonessential | *None* | | 0 to Infinity | *None*
| |

AMPK Activity | AMPK | | -Infinity to Infinity | Cardiac AMPK Assay | |

antibody | *None* | | -Infinity to Infinity | *None*
| |

antigen | *None* | | -Infinity to Infinity | *None*
| |

aortic arch (cross section) lesion area | *None* | (mm²) | 0 to Infinity | Quantification of atherosclerosis at the aortic sinus | |

Aortic Atherosclerosis Morphometry - Intimal Area | AAM-IA | (mm²) | -Infinity to Infinity | Atherosclerotic Morphometry in Pigs | |

Aortic Atherosclerosis Morphometry - Intimal Area as % Medial Area | AAM-IAMA | (%) | 0 to 100 | Atherosclerotic Morphometry in Pigs | |

Aortic Atherosclerosis Morphometry - Medial Area | AAM-MA | (mm²) | -Infinity to Infinity | Atherosclerotic Morphometry in Pigs | |

aortic flow 00 minutes | AF t00 | (ml/min) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

aortic flow 20 minutes | AF t20 | (ml/min) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

aortic flow 40 minutes | AF t40 | (ml/min) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

aortic flow 60 minutes | AF t60 | (ml/min) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

aortic lesion complexity index | LCI | | -Infinity to Infinity | *None*
| |

aortic pressure, mean | *None* | (mmHg) | -Infinity to Infinity | *None*
| |

aortic sinus (cross section) lesion area | *None* | (μm) | 0 to Infinity | Quantification of atherosclerosis at the aortic sinus | |

aortic surface area section A | AorticAreaSAA | (mm²) | 0 to Infinity | Quantification of atherosclerosis at the aortic sinus | |

aortic surface area section B | AorticAreaSAB | (mm²) | 0 to Infinity | Quantification of atherosclerosis at the aortic sinus | |

aortic surface area section C | AorticAreaSAC | (mm²) | 0 to Infinity | Quantification of atherosclerosis at the aortic sinus | |

apolipoprotein A | *None* | (mg/dL) | -Infinity to Infinity | *None*
| |

apolipoprotein B | *None* | (mg/dL) | -Infinity to Infinity | *None*
| |

apolipoprotein C3 | ApoC3 | (mg/dL) | 0 to 800 | *None*
| |

Arteriolar Hyalinosis | Arteriolar Hyalinosis | | -Infinity to Infinity | *None*
| |

aspartate | *None* | | 0 to Infinity | *None*
| |

aspartate amino transferase | AST | (U/L) | 0 to 1000 | *None*
| |

aspartate aminotransferase | AST | (U/L) | 0 to Infinity | *None*
| |

Assay Respiratory Control | RC | | -Infinity to Infinity | *None*
| |

average aortic leaflet A lesion | AorticLesA | (mm²) | 0 to Infinity | Quantification of atherosclerosis at the aortic sinus | |

average aortic leaflet B lesion | AorticLesB | (mm²) | 0 to Infinity | Quantification of atherosclerosis at the aortic sinus | |

average aortic leaflet C lesion | AorticLesC | (mm²) | 0 to Infinity | Quantification of atherosclerosis at the aortic sinus | |

average aortic lesion area | AALA | (µm²) | 0 to Infinity | *None*
| |

average clamp glucose | *None* | (mg/dL) | -Infinity to Infinity | *None*
| |

average glucose infusion rate | *None* | (mg/kg/min) | -Infinity to Infinity | *None*
| |

Basal Rate of Mitochondrial Respiration in the absence of added substrate | State 2 | (nmol O2.min-1.mgdw-1) | -Infinity to Infinity | Evaluation of Mitochondrial Function | |

basement membrane thickening | BMT | | 0 to Infinity | *None*
| |

beta-hydroxybutyrate | *None* | (µmol/l) | -Infinity to Infinity | *None*
| |

bicarbonate | *None* | (mEq/L) | -Infinity to Infinity | *None*
| |

bilirubin | *None* | (mg/dL) | -Infinity to Infinity | *None*
| |

bilirubin, direct | *None* | (mg/dL) | -Infinity to Infinity | *None*
| |

bilirubin, Total | total bilirubin | (mg/dL) | 0 to Infinity | *None*
| |

Bladder capacity | bladder capacity | (ml) | 0 to Infinity | *None*
| |

Bladder capacity - explant | Bladder capacity-e | (ml) | 0 to Infinity | *None*
| |

Bladder capacity - implant | Bladder capacity-i | (ml) | 0 to Infinity | *None*
| |

Bladder compliance - explant | B compliance-e | (mL/cm H2O) | 0 to Infinity | *None*
| |

Bladder compliance - implant | B compliance-i | (mL/cm H2O) | 0 to 250 | *None*
| |

Bladder pressure, capacity - explant | B press capacity-e | (cm H2O) | 0 to 250 | *None*
| |

Bladder pressure, capacity - implant | B press capacity-i | (cm H2O) | 0 to 250 | *None*
| |

Bladder pressure, empty - explant | B pressure empty-e | (cm H2O) | 0 to 250 | *None*
| |

Bladder pressure, empty - implant | B pressure empty-i | (cm H2O) | 0 to 250 | *None*
| |

Bladder weight | Bladder weight | (mg) | -Infinity to Infinity | *None*
| |

Bladder weight/body weight | Bladder weight/body | (mg/g) | -Infinity to Infinity | *None*
| |

blood pressure, mean arterial | *None* | (mmHg) | -Infinity to Infinity | *None*
| |

blood pressure: developed | DVP | (mmHg) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

blood pressure: developed 00 minutes | DVP t00 | (mmHg) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

blood pressure: developed 20 minutes | DVP t20 | (mmHg) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

blood pressure: developed 40 minutes | DVP t40 | (mmHg) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

blood pressure: developed 60 minutes | DVP t60 | (mmHg) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

blood pressure: diastole | dBP | (mmHg) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

blood pressure: diastole 00 minutes | dBP t00 | (mmHg) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

blood pressure: diastole 20 minutes | dBP t20 | (mmHg) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

blood pressure: diastole 40 minutes | dBP t40 | (mmHg) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

blood pressure: diastole 60 minutes | dBP t60 | (mmHg) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

blood pressure: mean arterial | aBP | (mmHg) | -Infinity to Infinity | *None*
| |

blood pressure: systole | sBP | (mmHg) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

blood pressure: systole 00 minutes | sBP t00 | (mmHg) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

blood pressure: systole 20 minutes | sBP t20 | (mmHg) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

blood pressure: systole 40 minutes | sBP t40 | (mmHg) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

blood pressure: systole 60 minutes | sBP t60 | (mmHg) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

body length A/N (rodent) | A/N (rodent) | (cm) | 0 to Infinity | *None*
| |

body mass | W rodent | (g) | 0 to 100 | *None*
| |

body surface area | BSA | (m²) | 0 to 4 | *None*
| |

body water, absolute amount | *None* | (g) | -Infinity to Infinity | *None*
| |

body water, free | free water | (g) | -Infinity to Infinity | *None*
| |

body weight (human) | W (human) | (kg) | 0 to 200 | *None*
| |

body weight (pig) | W pig | (kg) | 0 to Infinity | *None*
| |

bone area | bone area | (cm²) | -Infinity to Infinity | *None*
| |

bone mineral content | BMC | (g) | -Infinity to Infinity | *None*
| |

bone mineral density | BMD | (g/cm²) | -Infinity to Infinity | *None*
| |

brain mass | brain wt | (g) | 0 to 3 | *None*
| |

brain weight (rodent) | brain weight (rodent | (g) | 0 to Infinity | *None*
| |

BUN/Creatinine Ratio | Bun/Creatinine | (ratio) | 0 to Infinity | *None*
| |

calcium | *None* | (mg/dL) | -Infinity to Infinity | *None*
| |

calcium, blood | *None* | (mg/dL) | 0 to Infinity | *None*
| |

carbon dioxide production | VCO2 | (CO2/kg/hr) | -Infinity to Infinity | *None*
| |

carbon dioxide, blood | *None* | | 0 to Infinity | *None*
| |

cardiac efficiency | Ceff | (%) | 0 to 100 | Phenotypic Characterization of the Working Heart | |

cardiac efficiency 00 minutes | Ceff t00 | (%) | 0 to 100 | Phenotypic Characterization of the Working Heart | |

cardiac efficiency 20 minutes | Ceff t20 | (%) | 0 to 100 | Phenotypic Characterization of the Working Heart | |

cardiac efficiency 40 minutes | Ceff t40 | (%) | 0 to 100 | Phenotypic Characterization of the Working Heart | |

cardiac efficiency 60 minutes | Ceff t60 | (%) | 0 to 100 | Phenotypic Characterization of the Working Heart | |

cardiac ejection fraction | *None* | (%) | 0 to 100 | *None*
| |

cardiac function, intraventricular pressure: diastole | *None* | (mmHg) | -Infinity to Infinity | *None*
| |

cardiac function, intraventricular pressure: end diastole | *None* | (mmHg) | -Infinity to Infinity | *None*
| |

cardiac function, intraventricular pressure: systole | *None* | (mmHg) | -Infinity to Infinity | *None*
| |

cardiac output | *None* | | 0 to Infinity | *None*
| |

cardiac power 00 minutes | CP t00 | (mW/g) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

cardiac power 20 minutes | CP t20 | (mW/g) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

cardiac power 40 minutes | CP t40 | (mW/g) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

cardiac power 60 minutes | CP t60 | (mW/g) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

cardiac venous return | *None* | (ml/min) | -Infinity to Infinity | *None*
| |

chloride concentration | *None* | (U/kg) | -Infinity to Infinity | *None*
| |

chloride, blood | *None* | | 0 to Infinity | *None*
| |

cholesterol | *None* | (mg/dL) | -Infinity to Infinity | *None*
| |

cholesterol concentration in low density lipoproteins | *None* | (mg/dL) | -Infinity to Infinity | *None*
| |

cholesterol concentration in very low density lipoproteins | *None* | (mg/dL) | -Infinity to Infinity | *None*
| |

cholesterol remaining in intestinal lumen | *None* | (%) | -Infinity to Infinity | *None*
| |

cholesterol remaining in intestinal lymph | *None* | (%) | -Infinity to Infinity | *None*
| |

cholesterol remaining in intestinal mucosa | *None* | (%) | -Infinity to Infinity | *None*
| |

Cholesterol transported in lymph | Cholesterol in lymph | (%) | -Infinity to Infinity | *None*
| |

cholesterol, CM, plasma | CM-cholesterol | (mg/dL) | 0 to 10000 | *None*
| |

cholesterol, fractional clearance rate | CHOL FCR | (min) | -Infinity to Infinity | *None*
| |

cholesterol, HDL | *None* | (%) | -Infinity to Infinity | *None*
| |

cholesterol, HDL (COBAS) | HDL-COBAS | (mg/dL) | 0 to Infinity | *None*
| |

cholesterol, HDL (UC) | HDL-UC | (mg/dL) | 0 to Infinity | Ultracentrifugal separation of VLDL, LDL and HDL | |

Cholesterol, Hepatic Uptake | Hepatic CHOL uptake | (%) | -Infinity to Infinity | *None*
| |

cholesterol, splenic uptake | Splenic CHOL uptake | (%) | -Infinity to Infinity | *None*
| |

cholesterol, total | TC | (mg/dL) | 0 to Infinity | Lipid Profiles in Mice | |

cholesteryl ester fatty acids | *None* | (%) | 0 to 100 | *None*
| |

cholesteryl ester in chylomicrons | CE-CM | (% wt/wt) | -Infinity to Infinity | *None*
| |

cholesteryl esters | *None* | (µg/mg) | 0 to Infinity | *None*
| |

chylomicrons | *None* | (%) | -Infinity to Infinity | *None*
| |

Circumflex Coronary Artery Atherosclerosis Morphometry - Intimal Area | CIRCAM-IA | (mm²) | 0 to Infinity | Atherosclerotic Morphometry in Pigs | |

Circumflex Coronary Artery Atherosclerosis Morphometry - Intimal Area as % Medial Area | CIRCAM-IAMA | (%) | 0 to 100 | Atherosclerotic Morphometry in Pigs | |

Circumflex Coronary Artery Atherosclerosis Morphometry - Medial Area | CIRCAM-MA | (mm²) | -Infinity to Infinity | Atherosclerotic Morphometry in Pigs | |

Circumflex Coronary Artery Atherosclerosis Morphometry - Percent Stenosis | CIRCAM-%S | (%) | 0 to 100 | Atherosclerotic Morphometry in Pigs | |

citrate flux rate | *None* | (µMol/min/g) | -Infinity to Infinity | *None*
| |

citrate synthase flux rate | citrate synthase FR | | -Infinity to Infinity | *None*
| |

cleaved caspase-3 detection | *None* | | 0 to Infinity | *None*
| |

CoA ester, C16:0 | *None* | (nmol/g-tissue) | -Infinity to Infinity | *None*
| |

CoA ester, C16:1 | *None* | (nmol/g-tissue) | -Infinity to Infinity | *None*
| |

CoA ester, C18:0 | *None* | (nmol/g-tissue) | -Infinity to Infinity | *None*
| |

CoA ester, C18:1 | *None* | (nmol/g-tissue) | -Infinity to Infinity | *None*
| |

CoA ester, C18:2 | *None* | (nmol/g-tissue) | -Infinity to Infinity | *None*
| |

CoA ester, C18:3 | *None* | (nmol/g-tissue) | -Infinity to Infinity | *None*
| |

CoA esters, long-chain | *None* | (nmole) | -Infinity to Infinity | *None*
| |

complex lesions/total lesion ratio | C/total lesion | | -Infinity to Infinity | Quantification of atherosclerosis at the aortic sinus | |

Complexes | *None* | (bpm) | 0 to Infinity | *None*
| |

compliance | compliance | | -Infinity to Infinity | *None*
| |

coronary flow | CF | (ml/min) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

coronary flow 00 minutes | CF t00 | (ml/min) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

coronary flow 20 minutes | CF t20 | (ml/min) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

coronary flow 40 minutes | CF t40 | (ml/min) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

coronary flow 60 minutes | CF t60 | (ml/min) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

coronary flow/heart weight | CF/HW | (ml/min/g) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

corticosterone | *None* | (ng/ml) | -Infinity to Infinity | *None*
| |

corticosterone, plasma, arterial | *None* | (µg/mg) | 0 to Infinity | *None*
| |

creatinine, blood | blood creatinine | (mg/dL) | 0 to Infinity | *None*
| |

creatinine, plasma | plasma cre | (mg/dL) | 0 to Infinity | *None*
| |

creatinine, serum | SCR | (mg/dL) | 0 to Infinity | *None*
| |

creatinine, urine (Exocell Picric Acid method) | ucreat | (mg/dL) | 0 to Infinity | *None*
| |

creatinine, urine (spot) | ucreatinine-spot | (mg/dL) | -Infinity to Infinity | *None*
| |

creatinine, urine, 24h (HPLC) | UCreat-HPLC | (mg/dL) | -Infinity to Infinity | *None*
| |

diacyglycerols | *None* | (µg/mg) | 0 to Infinity | *None*
| |

diacylglycerol fatty acids | *None* | (%) | 0 to 100 | *None*
| |

DR | D | | -Infinity to Infinity | *None*
| |

dry heart weight | DHW | (g) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

duration of recording | *None* | (min) | 0 to Infinity | *None*
| |

early transmitral flow velocity | E | (m/s) | 0 to Infinity | Echocardiography: Mouse | |

EKG-Beginning to end of QRS complex | EKG-QRS | (msec) | -Infinity to Infinity | *None*
| |

EKG-Interval between R-waves | EKG-RR | (msec) | -Infinity to Infinity | *None*
| |

EKG-Interval between the peak of P-wave to Q-wave | EKG-PQ | (msec) | -Infinity to Infinity | *None*
| |

EKG-Interval between the peak of P-wave to R-wave | EKG-PR | (msec) | -Infinity to Infinity | *None*
| |

EKG-Interval between the peak of Q-wave to end of T-wave | EKG-QT | (msec) | -Infinity to Infinity | *None*
| |

EKG-Interval between the peak of S-wave to end of T-wave | EKG-ST | (msec) | -Infinity to Infinity | *None*
| |

EKG-Rate-corrected QT | EKG-QTc | (msec) | -Infinity to Infinity | *None*
| |

en face abdominal aorta lesion area | EFAbALA | (mm²) | -Infinity to Infinity | En face preparation and quantification of aortic surface area covered by atherosclerotic lesions | |

en face abdominal aorta lesion area % | EFAbALA% | (%) | 0 to 100 | En face preparation and quantification of aortic surface area covered by atherosclerotic lesions | |

En Face Abdominal Aorta Lesion Area (Pig) | EFAbALA (Pig) | (cm²) | -Infinity to Infinity | Atherosclerotic Morphometry in Pigs | |

En Face Abdominal Aorta Lesion Percent (Pig) | EFAbAL% (Pig) | (%) | 0 to 100 | Atherosclerotic Morphometry in Pigs | |

en face abdominal aorta total area | EFAbATA | (mm²) | -Infinity to Infinity | En face preparation and quantification of aortic surface area covered by atherosclerotic lesions | |

En Face Abdominal Aorta Total Area (Pig) | EFAbATA (Pig) | (cm²) | -Infinity to Infinity | Atherosclerotic Morphometry in Pigs | |

en face aortic arch lesion area | EFAALA | (mm²) | -Infinity to Infinity | En face preparation and quantification of aortic surface area covered by atherosclerotic lesions | |

en face aortic arch lesion area % | EFAALA% | (%) | 0 to 100 | En face preparation and quantification of aortic surface area covered by atherosclerotic lesions | |

en face aortic arch total area | EFAATA | (mm²) | -Infinity to Infinity | En face preparation and quantification of aortic surface area covered by atherosclerotic lesions | |

en face thoracic aorta lesion area | EFTALA | (mm²) | -Infinity to Infinity | En face preparation and quantification of aortic surface area covered by atherosclerotic lesions | |

en face thoracic aorta lesion area % | EFTALA% | (%) | 0 to 100 | En face preparation and quantification of aortic surface area covered by atherosclerotic lesions | |

en face thoracic aorta total area | EFTATA | (mm²) | -Infinity to Infinity | En face preparation and quantification of aortic surface area covered by atherosclerotic lesions | |

endothelial cell density | Mean_NV_ENDO | (num/µm³) | 0 to Infinity | *None*
| |

endothelial/mesangial cell number | Mean_N_EN_MES | (num/glomerulus) | 0 to Infinity | *None*
| |

endurance time | *None* | (min) | 0 to Infinity | *None*
| |

energy expenditure | *None* | (kcal/hr/kg) | -Infinity to Infinity | *None*
| |

energy expenditure, 30 min exercise | *None* | | 0 to Infinity | *None*
| |

energy expenditure, basal | *None* | | 0 to Infinity | *None*
| |

energy expenditure, exhaustion | *None* | | 0 to Infinity | *None*
| |

energy expenditure, maximum | *None* | | 0 to Infinity | *None*
| |

energy intake (24 hr) | *None* | (Kcal/day) | -Infinity to Infinity | *None*
| |

epinephrine, plasma, arterial | *None* | | 0 to Infinity | *None*
| |

euglycemic clamp | *None* | | 0 to Infinity | Glucose | |

exploratory activity | *None* | | 0 to Infinity | *None*
| |

fasting glucose | *None* | (mg/dL) | 0 to Infinity | *None*
| |

fasting insulin | *None* | | 0 to Infinity | *None*
| |

fat absorbtion, dietary | *None* | (%) | -Infinity to Infinity | *None*
| |

fat body mass | *None* | (g) | 0 to Infinity | *None*
| |

fat tissue mass | *None* | (g) | -Infinity to Infinity | *None*
| |

fat tissue, % | % body fat | (%) | 0 to 100 | *None*
| |

fat tissue, brown | BAT wt | (g) | 0 to 7 | *None*
| |

fat tissue, epidymal | epidymal fat wt | (g) | 0 to 7 | *None*
| |

fat tissue, periovarian | PFD wt | (g) | 0 to 7 | *None*
| |

fat tissue, retroperitoneal | retroperitoneal fat | (g) | 0 to 7 | *None*
| |

fat tissue, subcutaneous | subcutaneous fat wt | (g) | 0 to 7 | *None*
| |

fatty streaks/total lesion ratio | FS/total lesion | | 0 to Infinity | Quantification of atherosclerosis at the aortic sinus | |

Fecal Output | *None* | (g) | -Infinity to Infinity | *None*
| |

fenestrated endothelium | PCT_Fenestrated_Endo | (%) | 0 to 100 | *None*
| |

fenestrated endothelium opposite denuded basement membrane | PCT_Fen_endo_for_DGB | (%) | 0 to 100 | *None*
| |

filtration slit frequency | Mean_FSF | (num/mm) | 0 to Infinity | *None*
| |

foot process width | Mean_FPW | (nm) | 0 to Infinity | *None*
| |

fractional mesangial cell volume/glomerulus | Vv(MC/glom) | | 0 to 1 | *None*
| |

fractional mesangial matrix volume/glomerulus | Vv(MM/glom) | | 0 to 1 | *None*
| |

fractional mesangial volume/glomerulus | Vv(Mes/glom) | | 0 to 1 | *None*
| |

fractional shortening | *None* | | 0 to Infinity | Echocardiography: Mouse | |

Frequently sampled intravenous glucose tolerance test - Glucose Conc. | FSIGT-Glucose | (mg/dL) | -Infinity to Infinity | Frequently sampled intravenous glucose tolerance test | |

Frequently sampled intravenous glucose tolerance test - Insulin Conc. | FSIGT-Insulin | (mg/dL) | -Infinity to Infinity | Frequently sampled intravenous glucose tolerance test | |

GABA and glutamate | *None* | | 0 to Infinity | *None*
| |

GFR creatinine clearance (HPLC) | GFR HPLC | | 0 to Infinity | Creatinine Clearance by HPLC | |

GFR inulin clearance (FITC-inulin IV bolus injection) | GFR FITC | (µl/min) | 0 to 1500 | Determination of Glomerular Filtration Rate in Conscious Mice using FITC-inulin | |

GFR inulin clearance (osmotic mini-pump) | GFR Pump | | 0 to Infinity | Determination of Glomerular Filtration Rate in Conscious Mice using FITC-inulin | |

glomerular basement membrane - denuded | PCT_Denuded_GBM | (%) | 0 to 100 | *None*
| |

glomerular basement membrane thickness | GBM Width | (μm) | 0 to Infinity | *None*
| |

glomerular filtration rate | GFR | (ml/min) | -Infinity to Infinity | *None*
| |

glomerular volume | Glom Vol | (µm³) | 0 to Infinity | Podocyte Count and Density Analysis | |

glomerular volume per podocyte | GV/P | (µm³) | 0 to Infinity | Podocyte Count and Density Analysis | |

glomeruli globally sclerosed | PCT_Global_Sclerosis | (%) | 0 to 100 | *None*
| |

glomeruli number | Number_of_LM_Glomeru | | 0 to Infinity | *None*
| |

glucagon | *None* | (pg/ml) | -Infinity to Infinity | *None*
| |

glucagon, plasma, arterial | *None* | | 0 to Infinity | *None*
| |

gluconeogenesis rate | *None* | (mg/kg/min) | 0 to Infinity | *None*
| |

glucose appearance, endogenous | *None* | | -Infinity to Infinity | *None*
| |

glucose infusion rate | *None* | | -Infinity to Infinity | *None*
| |

glucose infusion rates | *None* | (mg/kg/min) | 0 to Infinity | *None*
| |

glucose metabolic index, brain | *None* | | 0 to Infinity | *None*
| |

glucose metabolic index, diaphragm | *None* | | 0 to Infinity | *None*
| |

glucose metabolic index, gastrocnemius | *None* | | 0 to Infinity | *None*
| |

glucose metabolic index, heart | *None* | | -Infinity to Infinity | *None*
| |

glucose metabolic index, soleus | *None* | | 0 to Infinity | *None*
| |

glucose metabolic index, superficial vastus lateralis | *None* | | 0 to Infinity | *None*
| |

glucose oxidation | *None* | (µMol/min/g) | -Infinity to Infinity | *None*
| |

glucose oxidation 00-20 minutes | Glox t00-t20 | (nmol/min/g) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

glucose oxidation 20-40 minutes | Glox t20-t40 | (nmol/min/g) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

glucose oxidation 40-60 minutes | Glox t40-t60 | (nmol/min/g) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

glucose production | *None* | (µMol/min/g) | -Infinity to Infinity | *None*
| |

glucose rate of appearance, endogenous | endo RA | (mg/kg/min) | -Infinity to Infinity | *None*
| |

glucose rate of disappearance | *None* | | -Infinity to Infinity | *None*
| |

glucose synthesis | *None* | (nmol/min/g) | -Infinity to Infinity | *None*
| |

glucose turnover, whole body | *None* | (mg/kg/min) | -Infinity to Infinity | *None*
| |

glucose uptake | *None* | (nmol/min/g) | -Infinity to Infinity | Glucose uptake in isolated cardiomyocytes. | |

glucose, arterial | *None* | (mg/dL) | -Infinity to Infinity | *None*
| |

glucose, basal | *None* | (mg/dL) | -Infinity to Infinity | *None*
| |

glucose, blood | blood glucose | (mg/dL) | 0 to Infinity | *None*
| |

glucose, blood, arterial | *None* | | -Infinity to Infinity | *None*
| |

glucose, clamp average | *None* | (mg/dL) | -Infinity to Infinity | *None*
| |

glucose, plasma | plasma glucose | (mg/dL) | 0 to Infinity | *None*
| |

glucose, rate of disappearance | Rd | (mg/kg/min) | -Infinity to Infinity | *None*
| |

glucose, urine | *None* | (mg/dL) | 0 to Infinity | *None*
| |

glutamate | *None* | | 0 to Infinity | *None*
| |

glutamine | *None* | | 0 to Infinity | *None*
| |

glutamine dehydrogenase | GLDH | (U/L) | 0 to Infinity | *None*
| |

glutamine rate of appearance in blood | *None* | | 0 to Infinity | *None*
| |

glutamine rate of disappearance in blood | *None* | | 0 to Infinity | *None*
| |

glutamine, blood, arterial | *None* | | 0 to Infinity | *None*
| |

glycerol | *None* | (µMol/min/g) | -Infinity to Infinity | *None*
| |

glycerol flux rate | glycerol FR | | -Infinity to Infinity | *None*
| |

glycerol fraction | glycerol fraction | | -Infinity to Infinity | *None*
| |

glycerol, plasma | *None* | (mg/dL) | 0 to 100 | *None*
| |

glycine | *None* | | 0 to Infinity | *None*
| |

glycogen flux rate | glycogen FR | | -Infinity to Infinity | *None*
| |

glycogen fraction | glycogen fraction | | -Infinity to Infinity | *None*
| |

glycogen synthesis | *None* | (nmol/min/g) | -Infinity to Infinity | *None*
| |

glycogen, gastrocnemius | *None* | | -Infinity to Infinity | *None*
| |

glycogen, heart | *None* | | -Infinity to Infinity | *None*
| |

glycogen, liver | *None* | | 0 to Infinity | *None*
| |

glycogen, muscle | *None* | | -Infinity to Infinity | *None*
| |

glycogen, superficial vastus lateralis | *None* | | 0 to Infinity | *None*
| |

glycogen/lipid synthesis, whole body | *None* | (mg/kg/min) | -Infinity to Infinity | *None*
| |

glycogenolytic rate | *None* | (mg/kg/min) | 0 to Infinity | *None*
| |

glycolysis | *None* | (nmol/min/g) | -Infinity to Infinity | *None*
| |

glycolysis 00-20 minutes | Glyc t00-t20 | (nmol/min/g) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

glycolysis 20-40 minutes | Glyc t20-t40 | (nmol/min/g) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

glycolysis 40-60 minutes | Glyc t40-t60 | (nmol/min/g) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

glycolysis, whole body | *None* | (mg/kg/min) | -Infinity to Infinity | *None*
| |

glycosylated hemoglobin | GHb | (%) | 0 to 30 | *None*
| |

HbA1c | HbA1c | (%) | 0 to 100 | *None*
| |

heart mass | cardiac muscle weigh | (g) | 0 to 3 | *None*
| |

heart rate | HR | (bpm) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

heart weight:tibia length ratio | Heart:TL | (g/mm) | 0 to Infinity | Morphometry: Mouse | |

heart:body weight ratio | Heart:BW | | 0 to Infinity | Morphometry: Mouse | |

heat | HEAT | (Kcal/hr) | -Infinity to Infinity | *None*
| |

Height (human) | Height | (cm) | 0 to 220 | *None*
| |

hematocrit | Hct | | 0 to Infinity | *None*
| |

hematocrit, arterial | *None* | (%) | -Infinity to Infinity | *None*
| |

Hematocrit, HCT | *None* | (%) | 0 to 100 | *None*
| |

hemoglobin | hemoglobin | (g/dL) | 0 to Infinity | *None*
| |

hepatic glucose production, basal | *None* | (mg/kg/min) | -Infinity to Infinity | *None*
| |

Hepatic Glucose Production, clamp | *None* | (mg/kg/min) | -Infinity to Infinity | *None*
| |

Histidine | *None* | | 0 to Infinity | *None*
| |

IL-6 concentration (ELISA) | IL-6 | | 0 to Infinity | *None*
| |

in vivo cardiac contractile performance | *None* | | 0 to Infinity | *None*
| |

Insulin 16.8 mM glucose | *None* | | 0 to Infinity | *None*
| |

Insulin 16.8 mM glucose + IBMX | *None* | | 0 to Infinity | *None*
| |

Insulin 5.6 mM glucose | *None* | | 0 to Infinity | *None*
| |

Insulin 5.6 mM glucose + tollbutamide | *None* | | 0 to Infinity | *None*
| |

insulin dose | *None* | (µMol/min/g) | -Infinity to Infinity | *None*
| |

Insulin Sensitivity | SI | (mu/L/min) | -Infinity to Infinity | Frequently sampled intravenous glucose tolerance test | |

insulin, arterial | *None* | (mg/dL) | -Infinity to Infinity | *None*
| |

insulin, basal | *None* | (ng/ml) | 0 to Infinity | *None*
| |

insulin, blood | *None* | (ng/dl) | 0 to Infinity | *None*
| |

insulin, clamp | *None* | (ng/ml) | 0 to Infinity | *None*
| |

insulin, experimental | *None* | | -Infinity to Infinity | *None*
| |

insulin, plasma | *None* | (pg/ml) | 5 to 500000 | *None*
| |

insulin, plasma, arterial | *None* | | 0 to Infinity | *None*
| |

insulin, serum | S Insulin | | 0 to Infinity | *None*
| |

intercontraction interval | intercontraction int | (sec) | -Infinity to Infinity | *None*
| |

interventricular septal diameter diastole | IVSd | (mm) | 0 to Infinity | Echocardiography: Mouse | |

interventricular septal diameter systole | IVSs | (cm) | 0 to Infinity | Echocardiography: Mouse | |

intraepidermal nerve fibers | IENF | (num/mm) | 1 to 50 | Prepare Plantar Footskin for Morphometry | |

intraperitoneal glucose tolerance test: 000min (baseline) | IPGTT t000 | (mg/dL) | 0 to Infinity | Intraperitoneal Glucose Tolerance Testing (IPGTT) | |

intraperitoneal glucose tolerance test: 005min post-injection | IPGTT t005 | (mg/dL) | 0 to Infinity | Intraperitoneal Glucose Tolerance Testing (IPGTT) | |

intraperitoneal glucose tolerance test: 015min post-injection | IPGTT t015 | (mg/dL) | 0 to Infinity | Intraperitoneal Glucose Tolerance Testing (IPGTT) | |

intraperitoneal glucose tolerance test: 030min post-injection | IPGTT t030 | (mg/dL) | 0 to Infinity | Intraperitoneal Glucose Tolerance Testing (IPGTT) | |

intraperitoneal glucose tolerance test: 060min post-injection | IPGTT t060 | (mg/dL) | 0 to Infinity | Intraperitoneal Glucose Tolerance Testing (IPGTT) | |

intraperitoneal glucose tolerance test: 120min post-injection | IPGTT t120 | (mg/dL) | 0 to Infinity | Intraperitoneal Glucose Tolerance Testing (IPGTT) | |

intravenous glucose tolerance | IVGTT | | 0 to Infinity | *None*
| |

isoleucine | *None* | | 0 to Infinity | *None*
| |

ketoisocaproic, blood, arterial | *None* | | 0 to Infinity | *None*
| |

ketones, urine | urine ketones | | -Infinity to Infinity | *None*
| |

Kf, brain | *None* | | 0 to Infinity | *None*
| |

Kf, diaphragm | *None* | | 0 to Infinity | *None*
| |

Kf, diaphragms | *None* | | 0 to Infinity | *None*
| |

Kf, gastrocnemius | *None* | | 0 to Infinity | *None*
| |

Kf, heart | *None* | | 0 to Infinity | *None*
| |

Kf, soleus | *None* | | 0 to Infinity | *None*
| |

Kf, superficial vastus laterlis | *None* | | 0 to Infinity | *None*
| |

Kg, adipose | *None* | (ml/100g/min) | 0 to Infinity | *None*
| |

Kg, brain | *None* | (ml/100g/min) | 0 to Infinity | *None*
| |

Kg, diaphragm | *None* | (ml/100g/min) | 0 to Infinity | *None*
| |

Kg, gastrocnemius | *None* | (ml/100g/min) | 0 to Infinity | *None*
| |

Kg, heart | *None* | (ml/100g/min) | 0 to Infinity | *None*
| |

Kg, soleus | *None* | (ml/100g/min) | 0 to Infinity | *None*
| |

Kg, superficial vastus lateralis | *None* | (ml/100g/min) | 0 to Infinity | *None*
| |

Kg, vastus lateralis | *None* | (ml/100g/min) | -Infinity to Infinity | *None*
| |

kidney weight:tibia length ratio | Kid:TL | (g/mm) | 0 to Infinity | Morphometry: Mouse | |

kidney, long-axis area | *None* | (cm) | 0 to Infinity | *None*
| |

kidney, long-axis area, right | right kidney LAArea | (cm) | 0 to Infinity | *None*
| |

kidney, long-axis circle | *None* | (cm) | 0 to Infinity | *None*
| |

kidney, long-axis circle, right | right kidney LACircl | (cm) | 0 to Infinity | *None*
| |

kidney, long-axis HGT | *None* | (cm) | 0 to Infinity | *None*
| |

kidney, long-axis HGT, right | right kidney LAHGT | (cm) | 0 to Infinity | *None*
| |

kidney, long-axis LGT | *None* | (cm) | 0 to Infinity | *None*
| |

kidney, long-axis LGT, right | right kidney LALGT | (cm) | 0 to Infinity | *None*
| |

kidney, short-axis area, right | right kidney SAArea | (cm) | 0 to Infinity | *None*
| |

kidney, short-axis circle | *None* | (cm) | 0 to Infinity | *None*
| |

kidney, short-axis circle, right | right kidney SACircl | (cm) | 0 to Infinity | *None*
| |

kidney, short-axis HGT | *None* | (cm) | 0 to Infinity | *None*
| |

kidney, short-axis HGT, right | right kidney SAHGT | (cm) | 0 to Infinity | *None*
| |

kidney, short-axis LGT | *None* | (cm) | 0 to Infinity | *None*
| |

kidney, short-axis WDT | *None* | (cm) | 0 to Infinity | *None*
| |

kidney, short-axis WDT, right | right kidney SAWDT | (cm) | 0 to Infinity | *None*
| |

lactate dehydrogenase | lactate dehydrogenas | (U/L) | 0 to Infinity | *None*
| |

Langerhans cells | LC | (num/mm) | -Infinity to Infinity | *None*
| |

lean body mass | *None* | (g) | -Infinity to Infinity | *None*
| |

lean tissue mass | *None* | (g) | -Infinity to Infinity | *None*
| |

lean tissue, % | % lean mass | (%) | 0 to 100 | *None*
| |

Left Anterior Descending Coronary Artery Morphometry - Intimal Area | LADCAM-IA | (mm²) | 0 to Infinity | Atherosclerotic Morphometry in Pigs | |

Left Anterior Descending Coronary Artery Morphometry - Intimal Area as % Medial Area | LADCAM-IAMA | (%) | 0 to 100 | Atherosclerotic Morphometry in Pigs | |

Left Anterior Descending Coronary Artery Morphometry - Medial Area | LADCAM-MA | (mm²) | 0 to Infinity | Atherosclerotic Morphometry in Pigs | |

Left Anterior Descending Coronary Artery Morphometry - Percent Stenosis | LADCAM-%S | (%) | 0 to 100 | Atherosclerotic Morphometry in Pigs | |

left atrial pressure | *None* | (mmHg) | -Infinity to Infinity | *None*
| |

left kidney weight (mouse) | L Kid Wt | (g) | 0 to 3 | Morphometry: Mouse | |

left ventricle interior diameter, end systoloic | LVID-end systoloic | (mm) | 0 to Infinity | *None*
| |

left ventricle anterior wall thickness, end diastolic | LVAWT-end diastolic | (mm) | 0 to Infinity | *None*
| |

left ventricle chamber diameter end diastolic | *None* | (mm) | -Infinity to Infinity | *None*
| |

left ventricle chamber diameter end systolic | *None* | (mm) | -Infinity to Infinity | *None*
| |

Left Ventricle End Diastolic Pressure | LVeDP | (mmHg) | -Infinity to Infinity | Measurement of Left Ventricular Hemodynamic Parameters in Intact Mice | |

left ventricle interior diameter, end diastolic | LVID-end diastolic | | 0 to Infinity | *None*
| |

left ventricle internal diameter end-diastole | *None* | (cm) | 0 to Infinity | *None*
| |

left ventricle internal diameter end-systole | *None* | (cm) | 0 to Infinity | *None*
| |

left ventricle mass | *None* | (g) | 0 to Infinity | *None*
| |

left ventricle posterior wall thickness end diastolic | LVPWT-end diastolic | (mm) | -Infinity to Infinity | *None*
| |

left ventricle posterior wall thickness end systolic | LVPWT-end systolic | (mm) | -Infinity to Infinity | *None*
| |

left ventricle posterior wall thickness end-diastole | LVPWT-end diaastole | (cm) | 0 to Infinity | *None*
| |

left ventricle posterior wall thickness end-systole | LVPWT-end systole | (cm) | 0 to Infinity | *None*
| |

left ventricle septal wall thickness end-diastole | LVSWT-end diastole | (cm) | 0 to Infinity | *None*
| |

left ventricle septal wall thickness end-systole | LVSWT-end systole | (cm) | 0 to Infinity | *None*
| |

left ventricle septum wall thickness end diastolic | LVSWT-end diastole | (mm) | -Infinity to Infinity | *None*
| |

left ventricle septum wall thickness end systolic | LVSWT-end systolic | (mm) | -Infinity to Infinity | *None*
| |

left ventricular cavity size | LV cavity size | (mm) | 0 to Infinity | Echocardiography: Mouse | |

left ventricular diameter diastolic | LVDd | (cm) | 0 to Infinity | Echocardiography: Mouse | |

left ventricular diameter systolic | LVDs | (cm) | 0 to Infinity | Echocardiography: Mouse | |

left ventricular ejection fraction | LV ejection fraction | (%) | 0 to Infinity | Echocardiography: Mouse | |

left ventricular mass | LV mass | (mg) | 0 to Infinity | Echocardiography: Mouse | |

left ventricular minute work | LV Minute work | (mEq/L) | -Infinity to Infinity | *None*
| |

left ventricular outflow index | LVOT VTI | (cm) | 0 to Infinity | Echocardiography: Mouse | |

left ventricular posterior wall diameter in diastole | LVPWd | (mm) | 0 to Infinity | Echocardiography: Mouse | |

left ventricular systolic pressure | LVSP | (mmHg) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

left ventricular wall thickness | LV wall thickness | | 0 to Infinity | Echocardiography: Mouse | |

leptin | *None* | (ng/dl) | -Infinity to Infinity | *None*
| |

leptin (RIA) | Leptin | | 0 to Infinity | *None*
| |

leucine | *None* | | 0 to Infinity | *None*
| |

leucine appearance reciprocal model rate | *None* | | 0 to Infinity | *None*
| |

leucine disappearance rate | *None* | | 0 to Infinity | *None*
| |

leucine, blood, arterial | *None* | | 0 to Infinity | *None*
| |

lipids, blood | *None* | (mg/dL) | 0 to Infinity | *None*
| |

lipoprotein, intermediate density | *None* | | 0 to Infinity | *None*
| |

lipoproteins, alpha | *None* | (%) | -Infinity to Infinity | *None*
| |

lipoproteins, beta | *None* | (%) | -Infinity to Infinity | *None*
| |

lipoproteins, LDL | *None* | | 0 to Infinity | *None*
| |

lipoproteins, pre-beta | *None* | (%) | -Infinity to Infinity | *None*
| |

liver mass | Liver Wt | (g) | 0 to 6 | *None*
| |

liver weight:tibia length ratio | Liver:TL | (g/mm) | 0 to Infinity | Morphometry: Mouse | |

liver:body weight ratio | Liver:BW | | 0 to Infinity | Morphometry: Mouse | |

low-density lipoprotein cholesterol | LDL | (mg/dL) | 0 to Infinity | Ultracentrifugal separation of VLDL, LDL and HDL | |

lymph flow | lymph flow | (ml/hr) | -Infinity to Infinity | *None*
| |

Lysine | *None* | | 0 to Infinity | *None*
| |

magnesium | *None* | (mEq/L) | -Infinity to Infinity | *None*
| |

mammary gland mass | Mammary wt | (g) | 0 to 3 | *None*
| |

Maximal ADP stimulated Mitochondrial Respiration Rate | State 3 | (nmol O2.min-1.mgdw-1) | -Infinity to Infinity | Evaluation of Mitochondrial Function | |

mean axonal diameter | MAD | (μm) | 1 to 10 | Preparing Nerves for Morphometry | |

mean brachiocephalic artery lesion size | *None* | (µm²) | 0 to Infinity | Quantification of atherosclerosis at the aortic sinus | |

mean cell volume | MCV | (fL) | 0 to Infinity | *None*
| |

mean corpuscular hemoglobin | MCH | (pg) | 0 to Infinity | *None*
| |

mean corpuscular hemoglobin concentration | MCHC | (g/dL) | 0 to Infinity | *None*
| |

mean corpuscular volume | MCPV | | 0 to Infinity | *None*
| |

Mean fractional interstitial area | Mean_FIA | (%) | 0 to 100 | *None*
| |

Mean fractional mesangial area | Mean_AA_MES | (%) | 0 to 100 | *None*
| |

mean platelet volume | MPV | | 0 to Infinity | *None*
| |

Mean surface area | Mean_SV | (µm²/µm³) | 0 to Infinity | *None*
| |

mean surface area per glomerulus | SA_using_LM_Means | (µm²) | 0 to Infinity | *None*
| |

mean void volume | mean void volume | (ml) | -Infinity to Infinity | *None*
| |

mean void volume (24 hour) | mvv (24 hour) | (ml/event) | -Infinity to Infinity | *None*
| |

mesangial cell density | Mean_NV_MES | (num/µm³) | 0 to Infinity | *None*
| |

mesangial index | PAS | (%PAS/glom) | 0 to 100 | Mesangial Index Quantification | |

Mesangial Sclerosis | Mesangial Sclerosis | | -Infinity to Infinity | *None*
| |

methionine | *None* | | 0 to Infinity | *None*
| |

micturition event | micturition event | | -Infinity to Infinity | *None*
| |

Mitochondrial Respiration in the absence of ATP synthesis | State 4 | (nmol O2.min-1.mgdw-1) | -Infinity to Infinity | Evaluation of Mitochondrial Function | |

muscle mass, skeletal | skeletal muscle weig | (g) | 0 to 3 | *None*
| |

myelinated fiber number | MF | | 1 to 10000 | Preparing Nerves for Morphometry | |

myocardial oxygen consumption | MVO2 | (µMol/min/g) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

myocardial oxygen consumption 00 minutes | MVO2 t00 | (ml/min/g) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

myocardial oxygen consumption 20 minutes | MVO2 t20 | (ml/min/g) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

myocardial oxygen consumption 40 minutes | MVO2 t40 | (ml/min/g) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

myocardial oxygen consumption 60 minutes | MVO2 t60 | (ml/min/g) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

NEFA | FFA | | -Infinity to Infinity | *None*
| |

NEFA oxidation | *None* | (umol/min/g) | -Infinity to Infinity | *None*
| |

NEFA oxidation, free | FFA OX | (µMol/min/g) | -Infinity to Infinity | *None*
| |

NEFA, arterial | *None* | | 0 to Infinity | *None*
| |

NEFA, in chylomicrons | FFA in CM | (% wt/wt) | -Infinity to Infinity | *None*
| |

NEFA, plasma | *None* | | -Infinity to Infinity | *None*
| |

NEFA, plasma, arterial | apNEFA | | -Infinity to Infinity | *None*
| |

NEFA, plasma, arterial, clamp | *None* | | -Infinity to Infinity | *None*
| |

NEFA, plasma, arterial, fatty acids | *None* | | -Infinity to Infinity | *None*
| |

NEFA, short-chain | *None* | (µg/mg) | 0 to Infinity | *None*
| |

negative pressure change/time | -dP/dt | (mmHg/sec) | -Infinity to Infinity | Measurement of Left Ventricular Performance in Langendorff Perfused Mouse Hearts | |

neointimal hyperplasia | Neo Hyperplasia | (µm²) | 0 to Infinity | *None*
| |

non-esterified free fatty acids | NEFA | (µmol/l) | 0 to Infinity | *None*
| |

norepinephrine, plasma, arterial | *None* | | 0 to Infinity | *None*
| |

octanoate oxidation | OCT OX | (µMol/min/g) | -Infinity to Infinity | *None*
| |

oral glucose tolerance | OGTT | | 0 to Infinity | *None*
| |

osmolality | *None* | (fL) | -Infinity to Infinity | *None*
| |

osmolality (Calculated) | osmolality | (mOsm/L) | 0 to Infinity | *None*
| |

oxygen consumption | VO2 | (O2/kg/hr) | -Infinity to Infinity | *None*
| |

oxygen consumption (Light Period) | VO2-L | (O2/kg/hr) | -Infinity to Infinity | *None*
| |

palmitate oxidation 00-20 minutes | Pox t00-t20 | (nmol/min/g) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

palmitate oxidation 20-40 minutes | Pox t20-t40 | (nmol/min/g) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

palmitate oxidation 40-60 minutes | Pox t40-t60 | (nmol/min/g) | 0 to Infinity | Phenotypic Characterization of the Working Heart | |

Pancreatic Insulin Content | PIC | (ng/µg) | 0.005 to 200 | Pancreatic Insulin Concentration | |

PEPCK | *None* | (µMol/min/g) | -Infinity to Infinity | *None*
| |

percent basophils | % baso | (%) | 0 to 100 | *None*
| |

percent body fat (Pig) | % body fat (Pig) | (%) | 0 to 100 | Serum, Blood and Body Weight Measurements in Pigs | |

percent body fat (rodent) | %BF (rodent) | (%) | 0 to 100 | *None*
| |

percent eosinophils | % eos | (%) | 0 to 100 | *None*
| |

percent lymphocytes | % lymphocytes | (%) | 0 to 100 | *None*
| |

percent monocytes | % mono | (%) | 0 to 100 | *None*
| |

percent neutrophils | % neutro | (%) | 0 to 100 | *None*
| |

percent of aortic surface covered by lesion | %AorticLes | (%) | 0 to 100 | Quantification of atherosclerosis at the aortic sinus | |

phenylalanine | *None* | | 0 to Infinity | *None*
| |

phenylalanine appearance in blood rate | *None* | | 0 to Infinity | *None*
| |

phenylalanine disappearance rate | *None* | | 0 to Infinity | *None*
| |

phenylalanine, blood, arterial | *None* | | 0 to Infinity | *None*
| |

phosphate, blood | *None* | (mg/dL) | 0 to Infinity | *None*
| |

phosphate, blood, inorganic | blood inorganic phos | (mg/dL) | 0 to Infinity | *None*
| |

Phosphatidyl choline | *None* | (µg/mg) | 0 to Infinity | *None*
| |

phosphatidyl ethanolamine | *None* | (µg/mg) | 0 to Infinity | *None*
| |

Phosphatidyl serine | *None* | (µg/mg) | 0 to Infinity | *None*
| |

phosphoenolpyruvate | *None* | (µMol/min/g) | -Infinity to Infinity | *None*
| |

Phosphoenolpyruvate carboxykinase flux rate | PEPCK FR | | -Infinity to Infinity | *None*
| |

phosphoenolpyruvate flux rate | PEP FR | | -Infinity to Infinity | *None*
| |

phosphoenolpyruvate fraction | PEP fraction | | -Infinity to Infinity | *None*
| |

phospholipid | *None* | (mg/dL) | -Infinity to Infinity | *None*
| |

phospholipid fatty acids | *None* | (%) | 0 to 100 | *None*
| |

phospholipids, chylomicrons | PL-CM | (% wt/wt) | -Infinity to Infinity | *None*
| |

plantar hind paw analgesia test | PHPAT | (sec) | 0 to 35 | Plantar Analgesia Test for Hind Paw and Tail | |

plasma adiponectin concentration (RIA) | pAdip | | 0 to Infinity | *None*
| |

plasma free fatty acids | FFA | (mg/dL) | 0 to Infinity | *None*
| |

plasma hepatic lipase activity | pHepLA | (mu/dL) | 0 to Infinity | *None*
| |

plasma PAI-1 concentration (ELISA) | pPAI-1 | | 0 to Infinity | *None*
| |

plasma triglycerides | pTG | (mg/dL) | 0 to Infinity | *None*
| |

plasma unesterified cholesterol | UC | (mg/dL) | 0 to Infinity | *None*
| |

platelet count | PLT | (10^3/mm3) | 0 to Infinity | *None*
| |

podocyte density | P/GVt | (num/µm³) | -Infinity to Infinity | *None*
| |

podocyte number | POD | (num/glomerulus) | 0 to Infinity | Podocyte Count and Density Analysis | |

positive pressure change/time | +dP/dt | (mmHg/sec) | -Infinity to Infinity | Measurement of Left Ventricular Performance in Langendorff Perfused Mouse Hearts | |

Post-op body weight (Rodent) | PostOPW rodent | (g) | 0 to 200 | *None*
| |

potassium, blood | *None* | | 0 to Infinity | *None*
| |

Pre-op body weight (Rodent) | PreOPW rodent | (g) | 0 to 200 | *None*
| |

pressure change/time maximum | dP/dt min | (mmHg/sec) | -Infinity to Infinity | Measurement of Left Ventricular Performance in Langendorff Perfused Mouse Hearts | |

pressure change/time minimum | dP/dt max | (mmHg/sec) | -Infinity to Infinity | Measurement of Left Ventricular Performance in Langendorff Perfused Mouse Hearts | |

pressure development, maximal rate | *None* | | -Infinity to Infinity | *None*
| |

proline | *None* | (µmol/l) | -Infinity to Infinity | *None*
| |

protein | *None* | (g/dL) | -Infinity to Infinity | *None*
| |

protein, chylomicrons | Protein-CM | (% wt/wt) | -Infinity to Infinity | *None*
| |

protein, total blood | *None* | | 0 to Infinity | *None*
| |

pulse | *None* | (bpm) | 0 to Infinity | *None*
| |

pyruvate cycling flux rate | PC FR | | -Infinity to Infinity | *None*
| |

pyruvate oxidation | PYRV OX | (ng/ml) | -Infinity to Infinity | *None*
| |

Rat Pressure Product (Developed Pressure time HR) | RPP | (mmHg/min) | -Infinity to Infinity | *None*
| |

red blood cell count | RBC | (10^3/mm3) | 0 to Infinity | *None*
| |

relative peak micturition pressure | rel peak mic pressur | (cm H2O) | -Infinity to Infinity | *None*
| |

relaxation, maximal rate | *None* | | -Infinity to Infinity | *None*
| |

Resistin | *None* | (ng/ml) | -Infinity to Infinity | *None*
| |

Respiratory Control | RC | | -Infinity to Infinity | Evaluation of Mitochondrial Function | |

respiratory exchange ratio | RQ | | -Infinity to Infinity | *None*
| |

respiratory exchange ratio (Light Period) | RER-L | | 0 to Infinity | *None*
| |

reticulocytes | Ret | | 0 to Infinity | *None*
| |

Rg, adipose | *None* | (umol/100g/min) | 0 to Infinity | *None*
| |

Rg, brain | *None* | (umol/100g/min) | 0 to Infinity | *None*
| |

Rg, diaphragm | *None* | (umol/100g/min) | 0 to Infinity | *None*
| |

Rg, gastrocnemeous | *None* | (umol/100g/min) | 0 to Infinity | *None*
| |

Rg, heart | *None* | (umol/100g/min) | 0 to Infinity | *None*
| |

Rg, soleus | *None* | (umol/100g/min) | 0 to Infinity | *None*
| |

Rg, vastus lateralis | *None* | (umol/100g/min) | 0 to Infinity | *None*
| |

Right Coronary Artery Atherosclerosis Morphometry - Intimal Area | RCAAM-IA | (mm²) | -Infinity to Infinity | Atherosclerotic Morphometry in Pigs | |

Right Coronary Artery Atherosclerosis Morphometry - Intimal Area as % Medial Area | RCAAM-IAMA | (%) | 0 to 100 | Atherosclerotic Morphometry in Pigs | |

Right Coronary Artery Atherosclerosis Morphometry - Medial Area | RCAAM-MA | (mm²) | -Infinity to Infinity | Atherosclerotic Morphometry in Pigs | |

Right Coronary Artery Atherosclerosis Morphometry - Percent Stenosis | RCAAM-%S | (%) | 0 to 100 | Atherosclerotic Morphometry in Pigs | |

right kidney weight (mouse) | R Kid Wt | (g) | 0 to Infinity | Morphometry: Mouse | |

RR systolic | RR systolic | (mmHg) | 0 to Infinity | *None*
| |

Sample Weight | sample weight | (mg) | -Infinity to Infinity | *None*
| |

sciatic min f-lat | *None* | | 0 to Infinity | Nerve Conduction Velocity Tests | |

sciatic motor amplitude | sciatic motor amp | | 0 to Infinity | Nerve Conduction Velocity Tests | |

sciatic motor conduction velocity | sciatic motor CV | (m/s) | 0 to Infinity | Nerve Conduction Velocity Tests | |

sciatic motor distal latency | sciatic motor DL | (msec) | 0 to Infinity | Nerve Conduction Velocity Tests | |

serines | *None* | | 0 to Infinity | *None*
| |

serium insulin: 000min (baseline) | S Insulin too | (nmole) | -Infinity to Infinity | *None*
| |

serium insulin: 030min (post injection) | S Insulin t30 | (nmole) | -Infinity to Infinity | *None*
| |

serum albumin | SAlb | (g/dL) | 0 to Infinity | *None*
| |

serum albumin to globulin ratio | A/G | (ratio) | 0 to Infinity | *None*
| |

serum amylase | S amylase | (U/L) | 0 to Infinity | *None*
| |

serum calcium | S calcium | (mg/dL) | 0 to Infinity | *None*
| |

serum chloride | Cl- | (mEq/L) | 0 to Infinity | *None*
| |

serum creatine phosphokinase | CPK | (U/L) | 0 to Infinity | *None*
| |

serum gamma glutamyl transpeptidase | GGTP | (U/L) | 0 to Infinity | *None*
| |

serum globulin | S Globulin | (g/l) | 0 to Infinity | *None*
| |

serum glutamic pyruvic transaminase | *None* | | 0 to Infinity | *None*
| |

serum ICAM-1 concentration (ELISA) | sICAM-1 | | 0 to Infinity | *None*
| |

serum lactic dehydrogenase | lactic dehydrogenase | | 0 to Infinity | *None*
| |

serum lipase | S lipase | (U/L) | 0 to Infinity | *None*
| |

serum magnesium | S magnesium | (mEq/L) | 0 to Infinity | *None*
| |

serum phosphorus | S phosphorus | (mg/dL) | 0 to Infinity | *None*
| |

serum potassium | K | (mEq/L) | 0 to Infinity | *None*
| |

serum sodium | Na | (mEq/L) | 0 to Infinity | *None*
| |

serum total bilirubin | S total bilirubin | (mg/dL) | 0 to Infinity | *None*
| |

serum total protein | S Total Protein | (g/dL) | 0 to Infinity | Serum, Blood and Body Weight Measurements in Pigs | |

serum triglycerides | TG | (mg/dL) | 0 to Infinity | Lipid Profiles in Mice | |

serum VCAM-1 concentration (ELISA) | sVCAM-1 | | 0 to Infinity | *None*
| |

small myelinated fiber frequency | small myf freq | (%) | 1 to 99 | Preparing Nerves for Morphometry | |

sodium, blood | *None* | | 0 to Infinity | *None*
| |

sphingomyelin | *None* | (µg/mg) | 0 to Infinity | *None*
| |

spleen weight | Spleen Wt | (g) | 0 to Infinity | Morphometry: Mouse | |

spleen weight:tibia length ratio | Spleen:TL | (g/mm) | 0 to Infinity | Morphometry: Mouse | |

spleen:body weight ratio | Spleen:BW | | 0 to Infinity | Morphometry: Mouse | |

sterol synthesis | *None* | | -Infinity to Infinity | *None*
| |

sub-epidermal nerve plexi | SNP | (num/mm) | 1 to 50 | Prepare Plantar Footskin for Morphometry | |

subcutaneous fat pad weight | subFPW | (g) | 0 to Infinity | *None*
| |

sural nerve conduction velocity | sural NCV | (m/s) | 5 to 70 | *None*
| |

tail compound muscle action potential | tail CMAP | | 0 to Infinity | *None*
| |

tail flick analgesia test | TFAT | (sec) | 0 to Infinity | Tail Flick | |

tail motor amplitude | tail motor amp | | 0 to Infinity | Nerve Conduction Velocity Tests | |

tail motor latency | tail motor L | (msec) | 0 to Infinity | Nerve Conduction Velocity Tests | |

tail sensory amplitude | TSA | | 0 to Infinity | Nerve Conduction Velocity Tests | |

tail sensory conduction velocity | tail sensory CV | (m/s) | 5 to 70 | Nerve Conduction Velocity Tests | |

tail sensory nerve action potential | tail SNAP | | 0 to Infinity | Nerve Conduction Velocity Tests | |

TAQ | A | | -Infinity to Infinity | *None*
| |

TCA cycle flux | VTCA | (µMol/min/g) | -Infinity to Infinity | *None*
| |

temperature, body | body temp | (°C) | 25 to 45 | *None*
| |

Thiobarbituric Acid Reactive Substances | TBARS | (mmol/L) | -Infinity to Infinity | *None*
| |

threonine | *None* | | 0 to Infinity | *None*
| |

tibia length (mouse) | Tibia L | (mm) | 0 to Infinity | Morphometry: Mouse | |

Time to Peak Pressure | *None* | (10^3/mm3) | -Infinity to Infinity | *None*
| |

total activity | *None* | | 0 to Infinity | *None*
| |

total albumin excretion | total ualb | (µg) | 0 to Infinity | *None*
| |

total aortic surface area | TotAorticSA | (mm²) | 0 to Infinity | Quantification of atherosclerosis at the aortic sinus | |

total body weight | *None* | (g) | -Infinity to Infinity | *None*
| |

total creatinine excretion | total creat | (mg) | 0 to Infinity | *None*
| |

total kidney weight (mouse) | Tot Kid Wt | (g) | 0 to 3 | Morphometry: Mouse | |

total kidney:body weight ratio | Kid:BW | | 0 to Infinity | Morphometry: Mouse | |

total length of epidermal:dermal border | LengthED | (mm) | -Infinity to Infinity | *None*
| |

total lesion area on the aorta | AorticLA | (mm²) | 0 to Infinity | Quantification of atherosclerosis at the aortic sinus | |

total mesangial cell volume | Tot Mesangial CV | (µm³) | 0 to Infinity | *None*
| |

total mesangial matrix volume | Tot Mes Matrix Vol | (µm³) | 0 to Infinity | *None*
| |

total mesangium volume | Tot Mesangium Vol | (µm³) | 0 to Infinity | *None*
| |

Total Radical-trapping Antioxidant Parameter | TRAP | | 0 to Infinity | TRAP | |

triglyceride pool enrichment | TG POOL | | -Infinity to Infinity | *None*
| |

triglyceride remaining in intestinal lumen | TG in IL | (%) | -Infinity to Infinity | *None*
| |

triglyceride remaining in intestinal mucosa | TG in IM | (%) | -Infinity to Infinity | *None*
| |

triglyceride transported in lymph | TG in Lymph | (%) | -Infinity to Infinity | *None*
| |

triglyceride, CM | TG in CM | (mg/dL) | 0 to 10000 | *None*
| |

triglyceride, fatty acids | TGFA | (%) | 0 to 100 | *None*
| |

triglyceride, fractional clearance rate | TG FCR | (min) | -Infinity to Infinity | *None*
| |

triglyceride, HDL | TG in HDL | (mg/dL) | -Infinity to Infinity | *None*
| |

triglyceride, hepatic uptake | Hepatic TG uptake | (% wt/wt) | -Infinity to Infinity | *None*
| |

triglyceride, LDL | TG in LDL | (mg/dL) | -Infinity to Infinity | *None*
| |

triglyceride, splenic uptake | Splenic TG uptake | (U/L) | -Infinity to Infinity | *None*
| |

triglyceride, vLDL | TG in VLDL | (mg/dL) | -Infinity to Infinity | *None*
| |

triglycerides | TG | (mg/dL) | -Infinity to Infinity | *None*
| |

triglycerides in organ through extraction & determination | *None* | (U/L) | -Infinity to Infinity | *None*
| |

triglycerides, tissue | TG (tissue) | (mg/g tissue) | -Infinity to Infinity | *None*
| |

Tubulo-interstitial fibrosis | Tubulo-interstitial fibrosis | | -Infinity to Infinity | *None*
| |

tumor necrosis factor alpha concentration (ELISA) | TNFa | | 0 to Infinity | *None*
| |

tyrosines | *None* | | 0 to Infinity | *None*
| |

unesterified cholesterol | *None* | (µg/mg) | 0 to Infinity | *None*
| |

unesterified fatty acids | *None* | (µg/mg) | 0 to Infinity | *None*
| |

urea nitrogen, blood | BUN | (mg/dL) | 0 to Infinity | *None*
| |

urine albumin (Exocell Albulwell M ELISA) | ualb | (µg/ml) | 0 to Infinity | Urine Albumin ELISA (Albuwell M kit) | |

urine albumin (spot) | ualb-spot | (µg/ml) | 0 to Infinity | Urine Albumin ELISA (Albuwell M kit) | |

urine albumin/urine creatinine ratio | ACR | (µg/mg) | 0 to Infinity | Creatinine Companion Protocol Assay (Exocell) | |

urine albumin/urine creatinine ratio (spot) | ACR-spot | (µg/mg) | -Infinity to Infinity | Creatinine Companion Protocol Assay (Exocell) | |

urine output | urine output | (ml) | -Infinity to Infinity | *None*
| |

urine pH | urine pH | | 0 to 14 | *None*
| |

valine | *None* | | 0 to Infinity | *None*
| |

VCO2 30 Min Exercise | *None* | | 0 to Infinity | *None*
| |

VCO2 basal | *None* | | 0 to Infinity | *None*
| |

VCO2 exhaustion | *None* | | 0 to Infinity | *None*
| |

VCO2 max | *None* | | 0 to Infinity | *None*
| |

very-low density lipoprotein cholesterol | VLDL | (mg/dL) | 0 to Infinity | Ultracentrifugal separation of VLDL, LDL and HDL | |

VO2 30 min exercise | *None* | | 0 to Infinity | *None*
| |

VO2 basal | *None* | | 0 to Infinity | *None*
| |

VO2 Exhaustion | *None* | | 0 to Infinity | *None*
| |

VO2 max | *None* | | 0 to Infinity | *None*
| |

VO2, maximum | *None* | | -Infinity to Infinity | *None*
| |

water intake | water intake | (ml/kg/hr) | 0 to 4 | *None*
| |

wet heart weight (mouse) | W Hrt Wt | (g) | 0 to 3 | Morphometry: Mouse | |

wheel running day | *None* | | 0 to Infinity | *None*
| |

white blood cell count | WBC | (10^3/mm3) | 0 to Infinity | *None*
| |

Work Duration | *None* | (min) | 0 to Infinity | *None*
| |

WR max | *None* | | 0 to Infinity | *None*
| |